ImmuCell Corporation (ICCC) |
| 6.65 -0.02 (-0.3%) 01-13 16:00 |
| Open: | 6.63 |
| High: | 6.75 |
| Low: | 6.62 |
| Volume: | 15,684 |
| Market Cap: | 60(M) |
| PE Ratio: | 23.75 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 8.32 |
| Resistance 1: | 7.12 |
| Pivot price: | 6.20 |
| Support 1: | 6.11 |
| Support 2: | 5.48 |
| 52w High: | 7.6 |
| 52w Low: | 4.28 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| EPS | 0.280 |
| Book Value | 3.290 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.301 |
| Profit Margin (%) | 8.37 |
| Operating Margin (%) | 0.37 |
| Return on Assets (ttm) | 3.8 |
| Return on Equity (ttm) | 8.3 |
Mon, 12 Jan 2026
Those who invested in ImmuCell (NASDAQ:ICCC) a year ago are up 25% - Yahoo Finance
Fri, 09 Jan 2026
ICCC: Shift to First Defense drives growth, with strong Q4 sales and asset reallocation after Re-Tain pause - TradingView — Track All Markets
Fri, 09 Jan 2026
ImmuCell reports Q4 sales of $7.6 million, shifts focus to First Defense - Investing.com Nigeria
Thu, 08 Jan 2026
Immucell Announces Impairment Charges and Strategic Refocus - TipRanks
Thu, 08 Jan 2026
Calf health company pauses one treatment to ramp a fast-growing product - Stock Titan
Wed, 07 Jan 2026
ImmuCell Corporation Announces Investor Conference Call to Discuss Strategic Shift and Q4 2025 Sales Results - Quiver Quantitative
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |